Search Results

You are looking at 1 - 10 of 53 items for :

  • Refine by Access: All x
Clear All
Full access

Biobehavioral Factors in Chemotherapy-Induced Nausea and Vomiting

Joseph A. Roscoe, Gary R. Morrow, Jane T. Hickok, Karen M. Mustian, and Abhay R. Shelke

) with high-dose metoclopramide in the control of cisplatin-induced emesis . N Engl J Med 1990 ; 322 : 816 – 821 . 19 Morrow GR Roscoe JA Hynes HE . Progress in reducing anticipatory nausea and vomiting: A study of community practice

Full access

Prevention of Emesis from Multiple-Day and High-Dose Chemotherapy Regimens

Rudolph M. Navari

of the side effects of chemotherapy: the influence of the 5HT 3 antagonists . Br J Cancer 1997 ; 76 : 1055 – 1061 . 2. Lachaine J Yelle L Kaizer L . Chemotherapy-induced emesis: quality of life and economic impact in the context of

Full access

The Evolution of Supportive Therapy of Emesis

Rodger J. Winn

Full access

Radiation-Induced Nausea and Vomiting

Susan Urba

syndrome. A memorial to William Michael Court-Brown . Clin Radiol 1979 ; 30 : 581 – 584 . 2. The Italian Group for Antiemetic Research in Radiotherapy . Radiation-induced emesis: a prospective observational multicenter Italian trial . Int J

Full access

Communicating About Chemotherapy-Induced Nausea and Vomiting: A Comparison of Patient and Provider Perspectives

John M. Salsman, Steven M. Grunberg, Jennifer L. Beaumont, Miriam Rogers, Diane Paul, Marla L. Clayman, and David Cella

acute emesis. 8 However, 40% to 60% of patients have symptoms in the delayed phase. 9 More recently, another class of antiemetics were introduced, the neurokinin-1 (NK1) receptor antagonists. The addition of NK1 receptor antagonists to standard therapy

Full access

Obstacles to the Implementation of Antiemetic Guidelines

Steven M. Grunberg

Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference . Ann Oncol 2006 ; 17 : 20 – 28

Full access

Antiemetic Studies on the NK1 Receptor Antagonist Aprepitant

John P. Stoutenburg and Harry Raftopoulos

modern antiemetics: perception vs. reality . Cancer 2004 ; 100 : 2261 – 2268 . 3 Roila F Donati D Tamberi S : Delayed emesis: incidence, pattern, prognostic factors and optimal treatment . Support Care Cancer 2002 ; 10 : 88 – 95

Full access

Antiemesis

David S. Ettinger, Debra K. Armstrong, Sally Barbour, Michael J. Berger, Philip J. Bierman, Bob Bradbury, Georgianna Ellis, Steve Kirkegaard, Dwight D. Kloth, Mark G. Kris, Dean Lim, Michael Anne Markiewicz, Lida Nabati, Carli Nesheiwat, Hope S. Rugo, Steven M. Sorscher, Lisa Stucky-Marshal, Barbara Todaro, and Susan Urba

.nccn.org .) These guidelines are also available on the Internet. For the latest update, please visit www.nccn.org . References 1 Laszlo J . Emesis as limiting toxicity in cancer chemotherapy . In: Laszlo J , ed. Antiemetics and Cancer

Full access

Antiemesis

Fox Chase Cancer Center

Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Cannabinoids for Symptom Management and Cancer Therapy: The Evidence

Mellar P. Davis

be superior to metoclopramide in breakthrough delayed nausea and vomiting from chemotherapy. 37 , 38 Olanzapine is as effective as aprepitant in reducing delayed emesis, and superior in reducing delayed nausea. Indirect comparisons are fraught with